Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988;103(1-2):73-82.
doi: 10.1007/BF01319810.

Herpes simplex virus type 1 infection in mice with severe combined immunodeficiency (SCID)

Affiliations

Herpes simplex virus type 1 infection in mice with severe combined immunodeficiency (SCID)

H Minagawa et al. Arch Virol. 1988.

Abstract

Herpes simplex virus type 1 (HSV-1) infection in mutant mice with severe combined immunodeficiency (SCID mice), i.e., mice in which the differentiation of both T and B lymphocytes is severely impaired, was studied. All control (infected and not treated with antibodies or with immune spleen cells) SCID mice were dead by 17 days after intracutaneous injection in the right midflank with 1 x 10(5) PFU of a virulent HSV-1 strain, Hayashida. Immunization with an avirulent strain of HSV-1 (SKa) did not protect them from death or prolong the survival time. Tissue virus titration of infected mice killed at various times after inoculation detected infectious virus in various organs, dorsal root ganglia, spinal cord, brain, kidney and adrenal gland in addition to the inoculation site of the skin in SCID mice, whereas virus could be detected only in the inoculation site and the nervous tissues in euthymic BALB/c mice, and in the adrenal gland from only one out of 17 nude mice. Human gamma globulin containing neutralizing antibody against HSV-1 prolonged the survival time but did not protect SCID mice from death. Transfer of spleen cells from immunized BALB/c mice protected the infected SCID mice from death. Treatment of spleen cells with anti-Thy 1.2 monoclonal antibody and complement abolished the protection.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Pathol. 1985 Sep;120(3):464-77 - PubMed
    1. Infect Immun. 1975 Jul;12(1):166-72 - PubMed
    1. Jpn J Med Sci Biol. 1984 Feb;37(1):35-9 - PubMed
    1. Arch Virol. 1987;96(1-2):1-15 - PubMed
    1. Jpn J Exp Med. 1969 Jun;39(3):223-32 - PubMed

MeSH terms